Lexeo Therapeutics, Inc. (LXEO)
D
Pipeline Grade
Financial Position (from SEC Filings)
$75.0M
Cash & Equivalents
$21.1M
Quarterly Burn Rate
11 mo
Est. Cash Runway
$378M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (6)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06976606 | A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM | OTHER | Recruiting | 40 |
| NCT06865482 | Clinical Course Of Disease In Participants With FA-CM | OTHER | Recruiting | 65 |
| NCT07050160 | Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant | OTHER | Enrolling By Invitation | 10 |
| NCT06109181 | Gene Therapy for ACM Due to a PKP2 Pathogenic Variant | PHASE2 | Active Not Recruiting | 10 |
| NCT05445323 | Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia | PHASE2 | Active Not Recruiting | 8 |
| NCT05400330 | Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease | PHASE1 | Active Not Recruiting | 10 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-15 | 8-K | Lexeo Therapeutics, Inc. (LXEO) (CIK 0001907108) - EX-99.2 | EDGAR |